

Full-year 2022 *results*



• With ten consecutive quarters of growth, the progress we've made in the past three years speaks for itself. As we launch the next phase of our strategy, our continued commitment to investing in the science will be crucial to maintaining a steady-state cadence of first and best in class medicines. •

Paul Hudson
Chief Executive Officer, Sanofi

Company sales and business EPS*

€42,997m

+7.0% (+13.9%)

Full-year 2022
company sales **



*Bradd Roberts, Scientist,
Analytical Science, Waterford, Ireland*

€8.26

+17.1% (+25.9%)

Full-year 2022
business EPS **

* Earnings per share

** Growth rates are expressed at constant exchange rates (CER).
Growth rates in parentheses are expressed on a reported basis.

Sales by global business unit



€16,457m
Specialty Care



€14,231m
General Medicines



Microglia



€7,229m
Vaccines



€5,080m
Consumer Healthcare

Sales by geography

US

€18,275m

Europe

€9,999m



*Nikita Khadse, Scientist,
R&D, Waltham, Massachusetts*

Rest of
the World

€14,723m

Latest regulatory milestones in Europe



Approval
of first and
only treatment
indicated for
**prurigo
nodularis**



First
approval
worldwide of
our new solution
for the prevention
of **respiratory
syncytial virus
disease**
in infants



Approval
of our
next-generation
booster
vaccine for
the prevention
of **COVID-19**
in adults



Approval
of new treatment
for adult patients
with **cold
agglutinin
disease**

For further information on full-year 2022 results and definitions of financial indicators, please refer to the press release issued on February 3, 2023 at: www.sanofi.com/en/investors

sanofi



@Sanofi



@Sanofi



@Sanofi



@SanofiaventisTVen